Orchestra BioMed (NASDAQ:OBIO) Raised to Hold at Wall Street Zen

Orchestra BioMed (NASDAQ:OBIO) was upgraded by equities research analysts at Wall Street Zen from a “strong sell” rating to a “hold” rating in a research note issued to investors on Saturday.

Several other equities research analysts have also recently weighed in on OBIO. Barclays upped their target price on Orchestra BioMed from $11.00 to $12.00 and gave the stock an “overweight” rating in a report on Friday, January 9th. TD Cowen assumed coverage on Orchestra BioMed in a research note on Wednesday, December 10th. They set a “buy” rating on the stock. Finally, Chardan Capital restated a “buy” rating and issued a $20.00 price objective on shares of Orchestra BioMed in a report on Thursday. One research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $13.80.

Orchestra BioMed Stock Performance

Shares of NASDAQ:OBIO opened at $4.20 on Friday. The firm’s 50 day simple moving average is $4.19 and its 200-day simple moving average is $3.84. The company has a debt-to-equity ratio of 0.32, a quick ratio of 4.72 and a current ratio of 4.73. Orchestra BioMed has a one year low of $2.20 and a one year high of $5.42. The firm has a market cap of $237.17 million, a PE ratio of -3.72 and a beta of 0.56.

Orchestra BioMed (NASDAQ:OBIO) last announced its quarterly earnings data on Thursday, March 12th. The company reported $0.26 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.38) by $0.64. Orchestra BioMed had a negative return on equity of 259.65% and a negative net margin of 157.40%.The company had revenue of $30.92 million for the quarter, compared to analysts’ expectations of $0.93 million. As a group, equities analysts predict that Orchestra BioMed will post -1.66 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. Vanguard Group Inc. raised its position in shares of Orchestra BioMed by 28.0% in the 3rd quarter. Vanguard Group Inc. now owns 1,481,875 shares of the company’s stock worth $3,675,000 after acquiring an additional 324,558 shares in the last quarter. Alyeska Investment Group L.P. bought a new stake in Orchestra BioMed during the third quarter valued at about $3,386,000. Pathstone Holdings LLC purchased a new position in Orchestra BioMed in the third quarter valued at about $2,495,000. Geode Capital Management LLC grew its stake in Orchestra BioMed by 22.4% in the fourth quarter. Geode Capital Management LLC now owns 473,363 shares of the company’s stock valued at $1,965,000 after purchasing an additional 86,564 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. raised its holdings in Orchestra BioMed by 46.2% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 263,788 shares of the company’s stock worth $1,095,000 after purchasing an additional 83,349 shares in the last quarter. 53.20% of the stock is currently owned by hedge funds and other institutional investors.

Orchestra BioMed Company Profile

Orchestra BioMed, Inc (NASDAQ: OBIO) is a clinical‐stage biopharmaceutical company dedicated to developing targeted therapies for inflammatory, fibrotic and oncologic diseases. The company’s research focuses on novel small-molecule programs designed to address high‐unmet-need conditions by leveraging proprietary prodrug and targeted inhibitor platforms. Orchestra BioMed’s pipeline includes lead candidates such as OBI-3424, a prodrug activated by AKR1C3 for the treatment of select solid tumors, and next-generation modulators aimed at suppressing pathological inflammation and fibrosis.

Orchestra BioMed conducts early‐ and mid-stage clinical studies in North America, working closely with key opinion leaders and academic centers to advance its programs.